Background. Female renal transplant candidates are prone to be sensitized by prior pregnancies, and undetected historical sensitization might decrease transplantation outcome. Hypothesis of our study was that pre-transplant blood transfusions (PTFs) can elucidate historical sensitization and that the avoidance of the associated antigens can improve transplantation outcome. Methods. Data from all female non-immunized renal transplant candidates who received a random PTF (rPTF) (n = 620), matched PTF (mPTF) (one HLA-A and B and one HLA-DR match) (n = 86) or donor-specific blood transfusion (DST) (n = 100) between 1996 and 2006 were collected. Complement-dependent cytoxicity was used to detect anti-HLA antibodies. Sensitization and transplantation outcomes after a PTF were analyzed. Non-immunized female renal transplant recipients who did not receive a PTF were used as the control group. Results. In 165 patients, anti-HLA antibodies (IgG) were detected after the PTF. Both historical and primary sensitizations were found. A DST induced donor-specific anti-HLA antibodies in 25% of the DST recipients. Our policy did not improve transplantation outcome in recipients of a kidney from a deceased donor (n = 368) or in recipients of a living donor [DST (n = 49) and mPTF (n = 66)]. Conclusions. A PTF did elucidate historical sensitization but induce primary sensitization as well. No beneficial effect of PTFs on transplantation outcome was found, and PTFs with the intention to detect historical sensitization are therefore not suggested.
Introduction
A positive historical crossmatch is associated with an increased risk of acute rejection and a decreased graft survival in renal transplantation [1] [2] [3] [4] [5] . All sexually active women are prone to be sensitized due to prior pregnancies or miscarriages, but the antibodies may have disappeared after several years. A historical positive crossmatch could therefore be missed in female renal transplant candidates. In a study by Mahanty et al., non-immunized women with more than two prior pregnancies who received a kidney from their offspring had a decreased graft survival [6] . Several case reports suggest that undetected sensitization plays a role in the decreased allograft survival in these patients [7, 8] .
Prior studies and clinical observations have shown that historical anti-HLA antibodies can become apparent after blood transfusions [9] . This was the rationale behind the practice in several Dutch transplantation centres to pretreat potentially sensitized female renal transplant candidates with a pre-kidney transplant blood transfusion (PTF). Our hypothesis is that a PTF improves the detection of historical anti-HLA antibodies and that avoidance of the associated antigens in a future donor kidney will improve graft survival.
The aim of the present study was to investigate how often historical sensitization is detected after a PTF and to find out if the avoidance of the associated antigens has a beneficial effect on transplantation outcome. To analyze the effect of a PTF on sensitization and transplantation outcome, we conducted a retrospective, multi-centre study in all seven Dutch transplantation centres.
Materials and methods
In the Dutch transplantation centres, three PTF protocols are used. One protocol for recipients planned to get a kidney from a deceased donor and two protocols for recipients planned to get a kidney from a living donor. A PTF was only administered to patients with a current negative complement-dependent cytotoxicity (CDC) screening, defined as the absence of relevant IgG anti-HLA antibodies.
Protocol 1: random PTF (rPTF)
One rPTF was given to all female recipients before they were entered on the waiting list for a kidney from a deceased donor in the four centres. The rPTF consisted of one unit of non-leukocyte-depleted packed cells, without buffy coat and less than 72 h old.
Protocol 2: donor-specific blood transfusion (DST)
One DST was given to all female recipients planned to get a kidney from a living donor. In two centres the DST consisted of one unit of nonleukocyte-depleted packed cells, without buffy coat and less than 72 h old, and in one centre an erythrocyte transfusion with buffy coat.
Protocol 3: matched PTF (mPTF)
One mPTF was given to all female recipients planned to get a kidney from a living donor. The mPTF consisted of one unit of non-leukocyte-depleted packed cells, without buffy coat and less than 72 h old. The aim was to obtain one HLA-A and one HLA-B and one HLA-DR match (broad) between the transfusion donor and the recipient. The mismatched HLA antigens of the intended organ donor were avoided in the transfusion donor.
Antibody screening
In all centres, pre-transplant screening was performed with the CDC for antibodies against HLA classes I and II. Specificity of anti-HLA antibodies was determined with the CDC. In all centres, specificity of anti-HLA class I antibodies was determined, and in all except one the specificity of anti-HLA class II antibodies was determined as well. Dithiothreitol (DTT) was added to exclude IgM anti-HLA antibodies and/or auto-antibodies.
Standard antibody screening was performed 2 and 4 weeks and 3 months after the PTF. Sensitization after a PTF was defined as the presence of IgG anti-HLA antibodies in the CDC. Screening was also done after all potentially sensitizing events according to the standards of the European Federation for Immunogenetics (EFI).
Transplantation criteria
A negative B-cell and T-cell crossmatch with all historic and the current serum was mandatory for transplantation. Transplantations with kidneys from deceased donors fulfilled the matching criteria of at least one DR match (HLA-DR matching on split level).
Parameters and definitions

Inclusion criteria
• One rPTF after 1 January 1996 or one mPTF or DST after 1 January 1998.
• Age ≥ 18 years.
• Female sex.
• No previous renal transplantation.
• No anti-HLA antibodies in the CDC before the pre-TX transfusion.
Baseline and follow-up data
All centres identified patients who received a PTF in the defined time period and fulfilled the inclusion criteria. Histocompatibility data were collected at the local HLA laboratories. From The Netherlands Organ Transplantation Registry (NOTR), we collected baseline and transplantation data. If data were incomplete, we contacted the transplant centre and searched for the data in regional databases or in the medical file.
Sensitization after a PTF
Historical sensitization was defined as the appearance of anti-HLA antibodies against antigens of the male partner or children of the recipient in the absence of anti-HLA antibodies against HLA antigens of the PTF donor. Primary sensitization was defined as the appearance of anti-HLA antibodies against antigens of the PTF donor in the absence of antibodies against HLA antigens of the partner or children. A judgement about the kind of sensitization was only possible when the HLA type of the PTF donor and the HLA type of the partner or children were known. In recipients of a DST, differentiation between historical or primary sensitization was impossible when the partner or a child was the donor. When a recipient had anti-HLA antibodies after a PTF these HLA antigens were unacceptable for a future kidney-donor combination.
To analyse the influence of HLA matches and mismatches between the recipient and the transfusion donor on sensitization, we counted the number of matches and mismatches on split level. For statistical analysis, we created the parameters HLA-ABDR matching (≥3 HLA-ABDR matches versus 0-2 HLA-ABDR matches) and HLA-DR matching (≥1 HLA-DR matches versus 0 HLA-DR matches).
Transplantation outcome
Control group
To evaluate the effect of the transfusion policies on transplantation outcome, we collected data from all adult female transplant recipients who did not receive a PTF. From these patients, all females without a previous transplantation and with a peak PRA <10%, who received a kidney from a deceased donor after 1 January 1996 or a kidney from a living donor after 1 January1998, were included in the control groups. Data were collected from the NOTR.
Clinical outcome
Graft loss was defined as loss of kidney function including death with a functioning graft. In death-censored graft Pre-kidney-transplant blood transfusions do not improve transplantation outcome 2561 survival, recipients who died with a functioning graft were censored at the time of death. Acute rejection was defined as any rejection treatment within the first 3 months after transplantation. In general, a transplant biopsy is done in all transplantation centres when an acute rejection is suspected.
Primary end-point. The primary end-point was the appearance of IgG anti-HLA antibodies (CDC) after a PTF (historical and primary anti-HLA antibodies).
Secondary end-points
• Difference in graft survival and death-censored graft survival between the transfusion groups and the control group.
• Difference in the rate and severity of acute rejections between the transfusion groups and the control group.
• Difference in renal function at 3 months and 1 year after transplantation between the transfusion groups and the control groups.
Statistical analysis
Results were expressed as the mean ± standard deviation for parametric data and as mean (range) for non-parametric data. Comparisons between groups were made with the independent t-test or one-way ANOVA when appropriate for continuous, parametric data. For non-parametric data, the Mann-Whitney U-test was used. For categorical variables, the chi-square test or Fisher's exact test was used. Kaplan-Meier curves were constructed for graft survival and death-censored graft survival. Differences between survival curves were calculated with the log-rank test. Multivariate Cox-proportional hazard analysis was used to correct for baseline differences between groups and identify independent predictors for graft failure. First univariate analyses were performed for all relevant parameters. All parameters with a P < 0.01 in the univariate analyses were included in the multivariate analysis. A backward stepwise method was used to define the final model.
Logistic regression was used to identify predictors for sensitization after a PTF and for acute rejection. A multivariate analysis was done following the previously mentioned method.
A P-value <0.05 was considered as significant. Statistical analyses were carried out with SPSS version 12.01.
Results
Anti-HLA antibodies after a PTF
Eight hundred and six recipients of a PTF fulfilled the inclusion criteria. Six hundred and twenty received an rPTF, 100 received a DST and 86 an mPTF. Among the DST recipients, 24 patients received erythrocytes with buffy coat and 76 patients received a non-leukocyte-reduced packed cell without buffy coat. Sixty patients received a DST from their spouse or offspring. The baseline characteristics of the three groups are given in Table 1 .
In 165 (20.1%) patients, anti-HLA antibodies (IgG) were detectable after the PTF. Anti-HLA antibodies were detectable in 131 of the rPTF recipients (21.1%), in 27 of the DST recipients (27%) and in 7 of the mPTF recipients (8.1%). In the multivariate logistic regression analysis, prior pregnancy and an mPTF were the only factors that were significantly related to the formation of anti-HLA antibodies. Prior pregnancy was associated with a more than 3-fold increased risk of sensitization. The risk of sensitization was almost 3-fold lower in recipients of an mPTF compared to recipients of a DST or rPTF. The complete logistic regression model is given in Table 2 .
Type of sensitization after a PTF
In 103 of the 165 patients with anti-HLA antibodies, both HLA types of the PTF donor and the partner and/or children were known. In 21 of these patients (20.3%), antibodies against the transfusion donor were detectable (primary sensitization), and in 15 patients (14.6%), the antibodies were directed against the partner and/or children (historical sensitization). In 67 patients (65.0%), the antibodies were directed against the PTF donor and the partner or children.
Transplantation outcome
Transplantation outcome in recipients of a kidney from a deceased donor (rPTF versus no rPTF)
From the 620 patients who received an rPTF, 368 patients were transplanted with a kidney from a deceased donor. Two hundred and four female recipients fulfilled the inclusion criteria for the control group. The baseline characteristics of the treatment and control groups are given in Table 3 . Patients in the treatment group were significantly younger, had a longer cold ischaemia and anastomosis time and more often received two instead of three immunosuppressive medicaments as initial immunosuppressive therapy. Delayed graft function occurred significantly more often in the control group. In one centre, data about prior pregnancies were not collected. In the control group, pregnancy status was therefore unknown in 54 patients.
Comparing the rPTF group with the control group, no significant differences were observed in graft survival, death censored graft survival (Figure 1) , cause of graft failure and serum creatinine levels at 3 months and 1 year after transplantation. Twenty-five patients (6.8%) in the rPTF group and eight patients (3.9%) in the control group lost their graft by rejection. No patients lost their graft by hyperacute rejection.
Donor age, DGF and time on dialysis appeared to be independent predictors for graft failure. A random PTF was no independent predictor for graft failure. The entire Cox regression model for graft survival is given in Table 4 .
Significantly more patients in the rPTF group experienced an acute rejection within 3 months after the transplantation [98 patients (27.0%) versus 24 patients (12.2%), P < 0.001] (Figure 2 ). related to an acute rejection in the first 3 months after renal transplantation. To evaluate differences in the severity of acute rejections, we analysed how many patients were additionally treated with OKT-3 or ATG. In the rPTF group, 38% of the patients with an acute rejection received OKT-3 or ATG versus 41% in the control group (not significant).
No significant differences in renal function at 3 months and 1 year after transplantation were observed between patients with an acute rejection in the rPTF and in the control group.
Comparing patients with (n = 75) and without (n = 293) anti-HLA antibodies after the rPTF, no significant differences were observed in waiting time and graft survival. 
Transplantation outcome in recipients of a kidney from a living donor (mPTF/DST versus no PTF)
Among the 100 patients who received a DST, 49 patients received a transplant from the intended kidney donor. In 25 patients, the transplantation with a kidney from the intended living donor was cancelled because the recipient had donor-specific anti-HLA antibodies after the DST. In the other 26 patients, the transplantation was cancelled for non-immunological reasons. Among the 86 patients who received an mPTF, 66 patients were transplanted with a kidney from the intended living donor. In this group, in only one patient the transplantation with a kidney from the intended kidney donor was cancelled because of donorspecific anti-HLA antibodies. One hundred and seventytwo patients fulfilled the inclusion criteria for the control group. The baseline characteristics of the three groups are given in Table 5 . No significant differences were observed in graft survival, death-censored graft survival ( Figure 3 ) and acute rejection rate within 3 months after transplantation, cause of graft failure and serum creatinine at 3 months and 1 year after transplantation between the three groups. In univariate analyses, none of the factors, including mPTF or DST, were significantly related to graft failure. No differences in acute rejection episodes within 3 months after the transplantation were observed between the three groups (21% in the DST group, 23% in the mPTF group and 14% in the control group, P > 0.05). In univariate analyses, an mPTF and a DST were not significantly related to acute rejection episodes within 3 months after the transplantation. Recipient age was the only factor that was significantly related to acute rejection [HR 0.98 (0.95-0.99), P < 0.05].
Discussion
The hypothesis of our study was that a PTF would improve graft survival by identifying historical sensitization in female renal transplant candidates. Although a PTF was helpful in identifying historical sensitization, most of the patients also had anti-HLA antibodies against antigens of the PTF donor, suggesting that a PTF was also associated with primary sensitization. Discrimination between primary and historical sensitization was based on the concept of antigen mismatches.
Duquesnoy et al. showed that antibody-antigen recognition is based on epitope recognition and immunogenic epitope mismatches [10] . Different HLA antigens share the same epitopes, and the appearance of antibodies against a new antigen might as well be the recognition of the same epitope on a different antigen. The molecular-based algorithm by Duquesnoy et al. might be a better way to analyse the kind of sensitization and should probably be used in future analysis. The conclusions on the incidence of primary and historical sensitizations in the current study are therefore of a limited value.
In our study, recipients of an mPTF had a significantly lower risk of sensitization compared to recipients from an rPTF or DST. Compared to recipients of an rPTF or a DST, recipients of an mPTF were much less exposed to HLA mismatches, meaning less epitope (triplet) mismatches. It is well known that sensitization increases with increasing triplet mismatches [11] . The results of our study are in agreement with the study from Lagaaij et al. in which it was clearly shown that sensitization occurs significantly less often in recipients of a one HLA-DR-matched blood transfusion [12] . Recipients of an mPTF all had one HLA-DR match with their PTF donor. After a DST, transplantation with the intended kidney donor was cancelled because of donor-specific HLA antibodies in 25% of the patients. In the literature, immunization levels after a DST differ widely [13] [14] [15] . This can be explained by the differences in populations that are investigated and the number of transfusions given in these studies.
In many countries, cell-based flow-cytometry or solid phase-based techniques, such as ELISA or Luminex, are used additionally for the detection of anti-HLA antibodies. It is possible that with these more sensitive techniques, some of the anti-HLA antibodies that were detected after a PTF could have been detected before the PTF was given. In The Netherlands, flow-cytometry, ELISA and Luminex techniques are being used but the CDC is considered as the golden standard because no firm evidence is available that anti-HLA antibodies found only by flow-cytometry, ELISA or Luminex (and not in the CDC) do have a negative effect on transplantation outcome [16] [17] [18] .
Although anti-HLA antibodies were detected after a PTF, our policy did not lead to an improvement of the graft survival in any of the groups. To our surprise, even more acute rejection episodes appeared in the transfusion groups. The question is why our policy did not improve transplantation outcomes. Several factors might explain our findings.
Firstly, the PTFs did not only identify historical sensitization, but also seem to induce primary sensitization. Opelz showed that an increased PRA is related to a lower graft survival [19] . This is most probably due to antibody reactivity against unrecognized mismatched HLA antigens or non-HLA antigens. Claas et al. showed that highly sensitized patients have comparable graft survival compared to unsensitized patients [20] . So the presence of anti HLA antibodies as such does not have a negative impact on transplantation outcome. And indeed in our study no difference is seen in graft survival between sensitized and non-sensitized patients, most probably related to a well-functioning screening and crossmatching programme.
Secondly, historical antibodies are only relevant when the recipient is re-exposed to the related HLA antigens [21] . However, female recipients who received a kidney from their spouse or offspring are always re-exposed and this finding seems somewhat contradictory because no significant difference in graft survival in this group between recipients of a DST or mPTF compared to non-transfused recipients was demonstrated. Assuming that 25% of the recipients of a kidney from their spouse or child in the control group (n = 47) would have been transplanted across a positive historical crossmatch, ∼50% of those patients should have lost their graft by rejection within 1 year of transplantation [4] . It would be expected that at least six patients in the control group would have lost their graft by rejection in the first year. In fact 94% of the patients in the control group had a functioning graft after 1 year and none of the failures were due to rejection. Our results suggest that historical antibodies identified after the administration of a PTF have no or little impact on graft survival.
Thirdly, acute rejections and the reaction on treatment have been related to a decreased graft survival [22] . In contrast, Starzl et al. postulated that some immune activation might be necessary to induce tolerance and that histopathological immune activation (low grade rejection) could theoretically represent the evolution of immunological tolerance rather than predicting graft loss [23] . Burlingham et al. showed that in transplantation with a one HLA haplotype mismatched kidney from a sibling donor, graft survival is higher when the donor has non-inherited maternal HLA antigens compared to non-inherited paternal HLA antigens. Paradoxically the incidence of early acute rejections was higher in these patients, suggesting that fetal and neonatal exposure results in immunologic priming [24] . Our data do not support these findings. As we mentioned before, an rPTF was an independent predictor for acute rejection but no differences were found in the relative number of severe acute rejections in the rPTF group as compared to the control group whereas in both groups the graft survival was the same. Prior studies showed that acute rejection rates were lower after PTFs [9, 25] .
Fourthly, the retrospective character and differences in baseline characteristics were a possible bias and a difference in transplantation outcome was therefore not found. In the recipients of a deceased donor, there were some baseline differences between the recipients of an rPTF and the control group. In recipients of an rPTF, the cold ischaemia time and anastomsis time were longer, less immunosuppression was given and as far as we know more patients had a prior pregnancy. In spite of these differences, no difference in graft survival was found. We cannot fully exclude that an rPTF was just able to compensate for the higher risk profile in the rPTF group. The results of the multivariate analysis in which an rPTF was not significantly related to graft failure do not support this theory. Besides, we do not think that the high risk of sensitization outweighs a possible small advantage in graft survival. In the recipients of a living donor, groups were too small for a multivariate analysis. Although a difference in transplantation outcome could have been missed here due to baseline differences or small numbers, we think that the high incidence of donor-specific anti-HLA antibodies in DST recipients gives enough evidence to abandon DSTs.
A fifth reason why we found no difference in graft survival could be that our follow-up was too short. Although we cannot exclude this, we think that it is unlikely that a significant difference will evolve in the long term, because most studies that found a difference in graft survival found a difference early after transplantation [12, 14, 26] .
In the past, several studies evaluated the effect of blood transfusions on graft survival and acute rejection rate. Before the introduction of calcineurin inhibitors, a major improvement in graft survival was seen in recipients of one or more PTFs [27] [28] [29] . In several animal studies, it is shown that blood transfusions can induce regulatory T cells and improve graft survival [30, 31] Since the introduction of calcineurin inhibitors, the effect of pre-transplant blood transfusions is controversial. Some studies could not find a significant advantage of PTFs [32, 33] , while others did find a significant difference [14, 26] . In the study by Marti et al. for instance, a significant better graft survival was found after the administration of two DSTs [14] . Major differences between this study and ours were that more than 60% of the patients were men and that two instead of one DST was given. Although there is substantial evidence that an immunological effect of blood transfusions exists, our study clearly shows the disadvantages of PTF in female renal transplant candidates. Our study further shows that a substantial effect of pre-transplant blood transfusions on graft survival is very unlikely.
In conclusion, PTFs do not elucidate unambiguously hidden or historic sensitization against HLA in female renal transplant recipients prone to be sensitized by pregnancy and primary sensitization occur as well. A clear answer to whether a PTF results in de novo sensitization is hampered by the antigen approach instead of an epitope (triplet) approach. An important finding was that a DST in female renal transplant recipients led to donor-specific sensitization in 25% of the patients. The findings within all other recipient groups do not justify the use of a DST; moreover, a DST should not be given anymore to avoid unnecessary sensitization against the intended donor.
The administration of one PTF (rPTF, mPTF, or DST) with the intention to detect historical sensitization and the avoidance of the associated antigens did not significantly influence transplantation outcome. Our policy even increased the number of acute rejections. PTFs are therefore not suggested in female renal transplant recipients, and on the basis of our results, PTFs have now been abandoned by all renal transplant centres in The Netherlands.
